Edition:
United Kingdom

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

46.10USD
18 May 2018
Change (% chg)

$-2.00 (-4.16%)
Prev Close
$48.10
Open
$48.75
Day's High
$49.55
Day's Low
$46.00
Volume
240,814
Avg. Vol
247,072
52-wk High
$68.05
52-wk Low
$24.05

Chart for

About

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The... (more)

Overall

Beta: --
Market Cap(Mil.): $2,492.82
Shares Outstanding(Mil.): 51.83
Dividend: --
Yield (%): --

Financials

  GBT.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -3.03 -- --
ROI: -31.74 -8.07 12.63
ROE: -32.19 -10.87 14.50

BRIEF-GBT Q1 Loss Per Share $0.87

* GBT REPORTS RECENT BUSINESS PROGRESS AND FIRST QUARTER 2018 FINANCIAL RESULTS

07 May 2018

BRIEF-Global Blood Therapeutics ‍priced underwritten public offering of 4.0 mln shares of its common stock

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF 4,000,000 SHARES OF COMMON STOCK

09 Mar 2018

BRIEF-Global Blood Therapeutics Announces Proposed Public Offering

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

08 Mar 2018

BRIEF-GBT Appoints David Johnson As Chief Commercial Officer

* GBT APPOINTS INDUSTRY LEADER DAVID L. JOHNSON AS CHIEF COMMERCIAL OFFICER Source text for Eikon: Further company coverage:

06 Mar 2018

BRIEF-Global Blood Therapeutics Q4 Loss Per Share $0.94

* GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

27 Feb 2018

BRIEF-GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease

* GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD) Source text for Eikon: Further company coverage:

09 Jan 2018

BRIEF-Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering

* GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING Source text for Eikon: Further company coverage:

15 Dec 2017

BRIEF-Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares

* GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

14 Dec 2017

Competitors

Earnings vs. Estimates